BioLineRx (NASDAQ:BLRX) Stock Crosses Above 200 Day Moving Average – What’s Next?

BioLineRx Ltd. (NASDAQ:BLRX) shares crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $3.73 and traded as high as $3.88. BioLineRx shares last traded at $3.85, with a volume of 28,850 shares changing hands.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Wall Street Zen raised shares of BioLineRx to a “sell” rating in a research report on Saturday, July 12th. HC Wainwright reissued a “buy” rating on shares of BioLineRx in a research report on Tuesday, June 17th. Finally, Jones Trading raised shares of BioLineRx from a “hold” rating to a “strong-buy” rating in a research report on Friday, May 30th. One analyst has rated the stock with a Strong Buy rating and one has given a Buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Strong Buy” and a consensus price target of $26.00.

BioLineRx Price Performance

The company has a quick ratio of 1.87, a current ratio of 2.06 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $16.40 million, a price-to-earnings ratio of -0.44 and a beta of 1.15. The stock’s 50-day moving average price is $4.22 and its 200 day moving average price is $3.73.

BioLineRx (NASDAQ:BLRX) last announced its earnings results on Thursday, August 14th. The biotechnology company reported ($1.00) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.65). BioLineRx had a negative return on equity of 49.74% and a negative net margin of 45.34%.The company had revenue of $0.30 million for the quarter, compared to analysts’ expectations of $0.66 million. Equities research analysts expect that BioLineRx Ltd. will post -5.8 earnings per share for the current fiscal year.

BioLineRx Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.